Fluticasone furoate nasal spray: Effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents

Abstract

Intranasal corticosteroids are widely prescribed for the treatment of perennial allergic rhinitis (PAR). The purpose of this study was to evaluate the efficacy and tolerability of intranasal fluticasone furoate, a novel enhanced-affinity glucocorticoid, in patients > or =12 years of age with PAR in a global, randomized, double-blind, placebo-controlled, 6-week study. Patients (n = 302) received fluticasone furoate nasal spray (FFNS) 110 microg or vehicle placebo once daily (q.d.). The primary efficacy measure was mean change from baseline over the 6-week treatment period in daily reflective total nasal symptom score (TNSS). Secondary end points included mean change from baseline in total and individual reflective nasal and ocular symptom scores and in daily peak nasal inspiratory flow (PNIF). FFNS was significantly more effective than placebo in reducing daily reflective TNSS over the treatment period (least square [LS] mean difference, -1.256; p < 0.001). Significant improvements were also established in total ocular symptom score (LS mean difference, -0.506; p = 0.004 versus placebo) and in all individual nasal (p < 0.001) and ocular (p < 0.03) symptoms assessed in a reflective manner. Improvements in daily PNIF were significantly greater with FFNS than placebo (LS mean difference, 8.376 L/minute; p = 0.004). FFNS was well tolerated. In this study, FFNS 110 microg q.d. was well tolerated and effective in reducing the nasal and ocular symptoms of PAR in adult and adolescent patients > or =12 years of age.

Allergic Conjunctivitis and the Impact of Allergic Rhinitis

“…Fluticasone furoate was associated with significant improvement compared with placebo in daily reflective eye redness score (P=0.01), but not in morning predose instantaneous eye redness score (P=0.076) [88].…”

Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology

“…Several studies have shown that the effects of mometasone, fluticasone and ciclesonide commence within a day of starting therapy (93). Intranasal corticosteroids probably also improve coexisting asthma (94-96) (A), and fluticasone furoate and mometasone may be effective for conjunctivitis (77,82,97) …”

“…Newer, once-daily products (e.g. fluticasone propionate (98), mometasone (99)(100)(101), fluticasone furoate nasal spray (82)) are preferred as these have been shown, unlike beclomethasone, not impair growth velocity albeit only after a year of therapy (102, 103) (A). This is probably due to the much lower systemic bioavailability of the newer products (Fig.…”

Should Intranasal Corticosteroids Be Used for the Treatment of Ocular Symptoms of Allergic Rhinoconjunctivitis? A Review of Their Efficacy and Safety Profile

“…Individuals with both nasal and ocular symptoms may benefit from INSs treatment. Indeed, recent clinical trial evidence in adults showed that INSs provided relief from the ocular symptoms of SAR/SAC [20,21,84,85,86,87]. However, few INSs have demonstrated this effect consistently in well-controlled clinical studies.…”